Welcome to our dedicated page for PARKERVISION SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on PARKERVISION's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into PARKERVISION's regulatory disclosures and financial reporting.
ParkerVision, Inc. registered 17,189,660 shares of common stock for resale under a prospectus supplement dated March 23, 2026. The registration aggregates three groups: (i) 1,273,540 shares tied to a 2016 private placement and warrant, (ii) up to 10,000,000 shares issued/issuable under a July 26, 2018 PIPE agreement with Aspire Capital, and (iii) 5,916,120 shares issuable upon conversion of 2018 convertible notes at fixed conversion prices.
The supplement states the company will not receive proceeds from resales by selling stockholders; however, it may receive proceeds if the 2016 warrant or Aspire-issued warrants are exercised. The prospectus supplement incorporates the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and attaches that 10-K as an update.
ParkerVision, Inc. files a Prospectus Supplement registering 12,800,000 shares of Common Stock for resale by selling stockholders under its April 19, 2019 prospectus. The registration covers up to 7,800,000 shares issuable on conversion of certain convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant.
The company states it will not receive proceeds from resales by selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 in gross proceeds, which it expects to use for patent enforcement and working capital. This supplement incorporates the Form 10-K filed March 23, 2026 and updates the Prospectus.
ParkerVision, Inc. reports another year of operating losses with a heavy reliance on patent litigation and licensing as its sole business. The company generated no licensing revenue in 2025 or 2024 and recorded a 2025 net loss of approximately $7.4 million, narrowing from $14.5 million in 2024.
At December 31 2025, ParkerVision held cash and cash equivalents of about $4.4 million, working capital of $2.3 million, and an accumulated deficit near $455.6 million. The auditor cited substantial doubt about its ability to continue as a going concern, reflecting recurring losses and negative operating cash flow.
The balance sheet is highly leveraged by litigation-related financing, including secured and unsecured contingent payment obligations with an estimated fair value of roughly $46.1 million and convertible notes of $3.1 million. To fund operations, the company continues to issue equity and depend on contingent litigation funding, which has led to significant dilution of shareholders.
ParkerVision, Inc. reported a 2025 net loss of $7.4M, an improvement from a $14.5M loss in 2024, mainly due to a $0.6M gain from revaluing contingent payment obligations versus a $9.6M loss in 2024. Licensing revenue remained at zero and selling, general and administrative expenses rose to $7.6M from $4.3M, driven partly by a $3.0M increase in share-based compensation, including a one-time $2.5M noncash option modification charge.
Cash and cash equivalents were $4.4M at December 31, 2025, with net cash used in operations of $5.1M. The company raised approximately $4.5M in November 2025 through a registered direct sale of 21.2M shares at $0.21 per share and in March 2026 issued 3.2M shares at $0.21 per share to settle $0.67M of upcoming convertible note maturities.
On the legal front, the Court of Appeals for the Federal Circuit granted an expedited schedule in the Qualcomm appeal, with briefing completed by March 23, 2026 and oral argument to follow. A planned jury trial against MediaTek in Waco, Texas was postponed after the judge requested further support for the company’s damages expert, with a new schedule to be set after updated reports and briefings.
ParkerVision, Inc. filed a prospectus supplement dated March 13, 2026 updating its resale prospectus to register 9,387,500 shares of Common Stock for resale by selling shareholders. The supplement states the company will receive no proceeds from those resales; Option exercises could yield up to $42,620 in gross proceeds.
The supplement incorporates a Form 8-K reporting exchange agreements under which the company issued 3,277,099 shares on March 13, 2026 in exchange for cancellation of convertible notes with aggregate principal of $675,000 plus accrued interest.
ParkerVision filed a Prospectus Supplement registering 16,638,353 shares of Common Stock for resale, representing shares issuable upon conversion of previously disclosed convertible promissory notes at a fixed conversion price of $0.13 per share.
The supplement attaches a Form 8-K reporting that on March 13, 2026 the company completed exchange agreements under Section 3(a)(9), issuing an aggregate of 3,277,099 shares of Common Stock at an exchange price of $0.21 per share to cancel Exchange Notes with aggregate principal of $675,000 and accrued interest of approximately $13,200.
ParkerVision, Inc. filed a Prospectus Supplement registering the resale of 1,578,946 shares of common stock, consisting of 1,052,631 issued shares and 526,315 shares issuable upon exercise of warrants. The selling stockholder will receive proceeds from any resale; the company will not.
The supplement states the Company would receive up to $526,315 if the Warrants are exercised for cash and expects to use any proceeds for general working capital, including payment of litigation expenses. The supplement attaches a Form 8-K reporting that on March 13, 2026 the Company exchanged convertible notes for 3,277,099 shares at an exchange price of $0.21 per share in reliance on Section 3(a)(9), canceling notes with aggregate principal of $675,000 and accrued interest of approximately $13,200.
ParkerVision, Inc. registers 13,342,953 shares of Common Stock for resale under a prospectus supplement dated March 13, 2026. The resale registration covers shares held by selling stockholders and the company states it will not receive proceeds from those resales.
The supplement also attaches a Form 8-K reporting that the company issued an aggregate of 3,277,099 shares on March 13, 2026 in exchange for cancellation of convertible notes with aggregate principal of $675,000 and accrued interest of approximately $13,200 at an exchange price of $0.21 per share, using the Section 3(a)(9) exemption. The prospectus notes the company would receive up to $2,833,756 if certain warrants are exercised for cash.
ParkerVision, Inc. files a prospectus supplement registering 5,871,584 shares of Common Stock for resale by selling stockholders under its Prospectus dated September 2, 2020.
The supplement incorporates a Current Report on Form 8-K dated March 13, 2026, which reports that the company issued an aggregate of 3,277,099 shares of Common Stock on March 13, 2026 in exchange for cancellation of convertible promissory notes with an aggregate outstanding principal amount of $675,000 and accrued interest of approximately $13,200. The company states it will not receive proceeds from the resale of the registered shares.
ParkerVision, Inc. supplements its existing prospectus to register the resale of 16,809,295 shares of Common Stock by selling stockholders. The prospectus supplement explains that the registered shares consist of convertible-note conversions, private placements, shares issued for services and payables, and up to 5,000,000 and 200,000 shares issuable upon exercise of warrants held by Aspire Capital and Tailwinds, respectively.
The company states it will not receive proceeds from the resale by selling stockholders; however, if the Aspire and Tailwinds warrants are exercised for cash, the company would receive up to an aggregate of $3,900,000, which it expects to use for general working capital and corporate purposes. The supplement incorporates a Form 8-K dated March 13, 2026 describing exchange agreements that resulted in issuance of 3,277,099 shares to cancel convertible notes with aggregate principal of $675,000.